Compare MRNA & CPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | CPAY |
|---|---|---|
| Founded | 2010 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7B | 22.5B |
| IPO Year | 2018 | 2010 |
| Metric | MRNA | CPAY |
|---|---|---|
| Price | $52.60 | $320.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $34.27 | ★ $379.00 |
| AVG Volume (30 Days) | ★ 5.3M | 522.2K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | 7.59 |
| EPS | N/A | ★ 15.03 |
| Revenue | ★ $19,263,000,000.00 | $4,528,403,000.00 |
| Revenue This Year | $8.74 | $18.83 |
| Revenue Next Year | $16.18 | $10.56 |
| P/E Ratio | ★ N/A | $20.98 |
| Revenue Growth | 4.29 | ★ 13.93 |
| 52 Week Low | $22.28 | $252.84 |
| 52 Week High | $59.55 | $361.99 |
| Indicator | MRNA | CPAY |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 60.47 |
| Support Level | $47.61 | $314.72 |
| Resistance Level | $54.94 | $333.12 |
| Average True Range (ATR) | 2.59 | 10.20 |
| MACD | -0.04 | 4.16 |
| Stochastic Oscillator | 73.61 | 96.35 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. The company offers payment and spend management solutions, including accounts payable automation, cross-border payments, commercial card programs, vehicle payment solutions, and lodging payment services. Its reportable segments are: Corporate Payments, Vehicle Payments, Lodging Payments and Other. The majority of the company's revenue is derived from the Vehicle Payments segment, which helps customers to pay for vehicle related expenses. Geographically, it derives the maximum revenue from the United States and the rest from Brazil, the United Kingdom and other countries.